Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/j.1365-2125.2006.02722.x http://scihub22266oqcxt.onion/10.1111/j.1365-2125.2006.02722.x 16869820!2000578!16869820     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=16869820&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Br+J+Clin+Pharmacol 2007 ; 63 (2): 216-23 Nephropedia Template TP {{tp|p=16869820|t=2007. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs |pdf=|usr=}}{{16869820}} gab.com Text In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs JO: Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=16869820 #FOAvip AIMS: QTc interval-prolonging drugs have been linked to cardiac arrhythmias, cardiac arrest and sudden death. In this study we aimed to quantify the risk of cardiac arrest associated with the use of non-antiarrhythmic QTc-prolonging drugs in an academic hospital setting. METHODS: We performed a case-control study in which patients, for whom intervention of the advanced life support resuscitation team was requested for cardiac arrest between 1995 and 2003 in the Academic Medical Centre, Amsterdam, were compared with controls regarding current use of non-antiarrhythmic QTc-prolonging drugs. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using unconditional logistic regression, adjusting for potential confounding factors. RESULTS: A statistically significant increased risk of cardiac arrest (OR 2.1, 95% CI 1.2, 3.5) was observed in patients who received QTc-prolonging drugs (42/140). The risk was more pronounced in patients receiving doses > 1 defined daily dose (OR 2.5, 95% CI 1.1, 5.9), patients taking > 1 QTc-prolonging drug simultaneously (OR 4.8, 95% CI 1.6, 14) and patients taking pharmacokinetic interacting drugs concomitantly (OR 4.0, 95% CI 1.2, 13). CONCLUSIONS: Use of non-antiarrhythmic QTc-prolonging drugs in hospitalized patients with several underlying disease is associated with an increased risk of cardiac arrest. The effect is dose related and pharmacokinetic drug-drug interactions increase the risk substantially. Physicians caring for inpatients should be made aware of the fact that these non-antiarrhythmic drugs may be hazardous, so that potential risks can be weighed against treatment benefits and additional cardiac surveillance can be requested, if necessary. Twit Text FOAVip In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs ????Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=16869820 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=16869820 #FOAvip English Wikipedia <ref>{{Cite pmid|16869820}}</ref> In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs #MMPMID16869820 De Bruin ML; Langendijk PN; Koopmans RP; Wilde AA; Leufkens HG; Hoes AW Br J Clin Pharmacol 2007[Feb]; 63 (2): 216-23 PMID16869820show ga AIMS: QTc interval-prolonging drugs have been linked to cardiac arrhythmias, cardiac arrest and sudden death. In this study we aimed to quantify the risk of cardiac arrest associated with the use of non-antiarrhythmic QTc-prolonging drugs in an academic hospital setting. METHODS: We performed a case-control study in which patients, for whom intervention of the advanced life support resuscitation team was requested for cardiac arrest between 1995 and 2003 in the Academic Medical Centre, Amsterdam, were compared with controls regarding current use of non-antiarrhythmic QTc-prolonging drugs. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using unconditional logistic regression, adjusting for potential confounding factors. RESULTS: A statistically significant increased risk of cardiac arrest (OR 2.1, 95% CI 1.2, 3.5) was observed in patients who received QTc-prolonging drugs (42/140). The risk was more pronounced in patients receiving doses > 1 defined daily dose (OR 2.5, 95% CI 1.1, 5.9), patients taking > 1 QTc-prolonging drug simultaneously (OR 4.8, 95% CI 1.6, 14) and patients taking pharmacokinetic interacting drugs concomitantly (OR 4.0, 95% CI 1.2, 13). CONCLUSIONS: Use of non-antiarrhythmic QTc-prolonging drugs in hospitalized patients with several underlying disease is associated with an increased risk of cardiac arrest. The effect is dose related and pharmacokinetic drug-drug interactions increase the risk substantially. Physicians caring for inpatients should be made aware of the fact that these non-antiarrhythmic drugs may be hazardous, so that potential risks can be weighed against treatment benefits and additional cardiac surveillance can be requested, if necessary. |*Anti-Arrhythmia Agents[MESH] |*Hospitalization[MESH] |Aged[MESH] |Cardiopulmonary Resuscitation[MESH] |Case-Control Studies[MESH] |Female[MESH] |Heart Arrest/*chemically induced[MESH] |Humans[MESH] |Long QT Syndrome/*drug therapy[MESH] |Male[MESH] |Middle Aged[MESH] |Risk Factors[MESH]In-hospital cardiac arrest is associated with use of non-antiarrhythmi(epmc).pdf DeepDyve Pubget Overpricing